The cash distribution is the primary value driver for RLYB holders; monitor the stockholder vote and closing conditions. The CVRs for legacy assets are likely low-value. Post-merger, the combined company will be a clinical-stage oncology biotech (Avenzo) with a $215M cash infusion, targeting Q4 2026 close. RLYB stock should trade near the expected cash distribution value until the vote.
Price Chart
Executive Summary
Rallybio Corp (RLYB) filed an S-4 registration statement for a proposed reverse merger with private biotech Avenzo Therapeutics. Under the terms, Rallybio will distribute substantially all of its net cash (~$83.2M as of June 30, 2026) to its stockholders as a Parent Distribution, and issue CVRs for legacy assets. Post-merger, Rallybio stockholders will own approximately 2.8% of the combined company, while Avenzo equityholders and concurrent financing investors will own ~56.6% and ~40.6%, respectively. The merger is expected to close in Q4 2026, subject to stockholder approval and other conditions.
Key Facts
- Rallybio to merge with Avenzo via reverse merger; Avenzo valued at $300M, Rallybio at $15M (post-distribution)
- Concurrent financing of $215M from investors; proceeds to fund combined company operations
- Rallybio stockholders to receive cash distribution of substantially all net cash (~$83.2M as of June 30, 2026) plus CVRs for legacy assets
- Post-merger ownership: pre-merger Avenzo holders ~56.6%, concurrent financing investors ~40.6%, Rallybio holders ~2.8%
- Rallybio to change name to Avenzo Therapeutics, Inc.; expected ticker AVZO on Nasdaq
- Reverse stock split (1-for-2 to 1-for-9) and authorized share increase from 200M to 500M proposed
- Rallybio board unanimously recommends voting FOR all proposals
Financial Impact
Rallybio stockholders to receive aggregate cash distribution of approximately $83.2M (estimated ~$15.7 per share based on 5.3M shares outstanding) plus CVRs for legacy assets with uncertain value. Combined company to have ~$215M in new cash from concurrent financing plus remaining Rallybio cash post-distribution.
Risk Factors
- Merger may not close if stockholder approval or other conditions are not met
- Actual cash distribution may be less than estimated due to transaction expenses and liabilities
- CVRs for legacy assets may expire worthless
- Combined company faces clinical and regulatory risks for Avenzo's pipeline (AVZO-021, AVZO-023, AVZO-1418, AVZO-103)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001193125-26-304966 |
| Document: d71655dex1036.htm | 0001193125-26-304966 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $16.40 | awaiting T+60 | — | $15.93 (−2.87%) |
Oct 26, 2026 1d ago | 8-K | $16.65 | awaiting T+60 | — | $15.93 (−4.32%) |
Oct 16, 2026 11d ago | EFFECT | $16.28 | awaiting T+60 | — | $15.93 (−2.15%) |
Oct 14, 2026 13d ago | S-4/A | $16.78 | awaiting T+60 | — | $15.93 (−5.04%) |
Jul 15, 2026 14w ago | S-4 | $15.96 $17.02 | ▲ +6.64% | ▲ +2.93% | $15.93 (−0.19%) |
Jun 1, 2026 21w ago | 425 | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.93 (−5.57%) |
Jun 1, 2026 21w ago | 8-K | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.93 (−5.57%) |
May 4, 2026 25w ago | 8-K | $14.12 $15.96 | ▲ +13.03% | ▲ +11.17% | $15.93 (+12.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers